Search Results - "Dillon, John F"

Guidelines on the management of abnormal liver blood tests by Newsome, Philip N, Cramb, Rob, Davison, Suzanne M, Dillon, John F, Foulerton, Mark, Godfrey, Edmund M, Hall, Richard, Harrower, Ulrike, Hudson, Mark, Langford, Andrew, Mackie, Anne, Mitchell-Thain, Robert, Sennett, Karen, Sheron, Nicholas C, Verne, Julia, Walmsley, Martine, Yeoman, Andrew

“…These updated guidelines on the management of abnormal liver blood tests have been commissioned by the Clinical Services and Standards Committee (CSSC) of the…”
Get more information

A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments by Radley, Andrew, Robinson, Emma, Aspinall, Esther J, Angus, Kathryn, Tan, Lex, Dillon, John F

“…Direct Acting Antiviral (DAAs) drugs have a much lower burden of treatment and monitoring requirements than regimens containing interferon and ribavirin, and a…”
Get full text

Accuracy of Non-Invasive Imaging Techniques for the Diagnosis of MASH in Patients With MASLD: A Systematic Review by Cathcart, Jennifer, Barrett, Rachael, Bowness, James S, Mukhopadhya, Ashis, Lynch, Ruairi, Dillon, John F

“…Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health problem. The secondary stage in MASLD is steatohepatitis (MASH),…”
Get full text

Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia by Ginnane, Joshua F, Scott, Nick, Radley, Andrew, Dillon, John F, Hellard, Margaret, Doyle, Joseph

“…Meeting the World Health Organisation 2030 target of treating 80% of people with hepatitis C virus (HCV) in Australia requires accessible testing and treatment…”
Get full text

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis by Gurun, Marc, Brennan, Paul, Handjiev, Sava, Khatib, Aseil, Leith, Damien, Dillon, John F, Byrne, Christopher J

“…Metabolic dysfunction associated steatotic liver disease (MASLD) increases the risk of incident chronic kidney disease (CKD). However, the relative risk of CKD…”
Get full text

Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles by Nicoletti, Paola, Aithal, Guruprasad P., Chamberlain, Thomas C., Coulthard, Sally, Alshabeeb, Mohammad, Grove, Jane I., Andrade, Raul J., Bjornsson, Einar, Dillon, John F., Hallberg, Par, Lucena, M. Isabel, Maitland‐van der Zee, Anke H., Martin, Jennifer H., Molokhia, Mariam, Pirmohamed, Munir, Wadelius, Mia, Shen, Yufeng, Nelson, Matthew R., Daly, Ann K.

“…Some patients prescribed flucloxacillin (~ 0.01%) develop drug‐induced liver injury (DILI). HLA‐B*57:01 is an established genetic risk factor for…”
Get full text

Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause‐specific outcomes by Innes, Hamish A., McDonald, Scott A., Dillon, John F., Allen, Sam, Hayes, Peter C., Goldberg, David, Mills, Peter R., Barclay, Stephen T., Wilks, David, Valerio, Heather, Fox, Ray, Bhattacharyya, Diptendu, Kennedy, Nicholas, Morris, Judith, Fraser, Andrew, Stanley, Adrian J., Bramley, Peter, Hutchinson, Sharon J.

“…Sustained viral response (SVR) is the optimal outcome of hepatitis C virus (HCV) therapy, yet more detailed data are required to confirm its clinical value…”
Get full text

Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2) by Sharma, Ritu S, Harrison, David J, Kisielewski, Dorothy, Cassidy, Diane M, McNeilly, Alison D, Gallagher, Jennifer R, Walsh, Shaun V, Honda, Tadashi, McCrimmon, Rory J, Dinkova-Kostova, Albena T, Ashford, Michael L.J, Dillon, John F, Hayes, John D

“…Background & Aims Nonalcoholic steatohepatitis (NASH) is associated with oxidative stress. We surmised that pharmacologic activation of NF-E2 p45-related…”
Get full text

Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison by Byrne, Christopher J, Malaguti, Amy, Inglis, Sarah Karen, Dillon, John F

“…ObjectivesHepatitis C virus (HCV) poses a global public health threat. Prisons are a focus of prevention efforts due to high infection burdens. Expedition of…”
Get full text

Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis by Chowdhry, Sudhir, Nazmy, Maiiada H., Meakin, Paul J., Dinkova-Kostova, Albena T., Walsh, Shaun V., Tsujita, Tadayuki, Dillon, John F., Ashford, Michael L.J., Hayes, John D.

“…Nonalcoholic steatohepatitis (NASH) arises from nonalcoholic fatty liver disease (NAFLD) as a consequence of oxidative stress. Herein we report that the…”
Get full text

Thrombocytosis and abnormal liver enzymes: A trigger for investigation of underlying malignancy by Gold, Lucy C, Macpherson, Iain, Nobes, Jennifer H, Dow, Eleanor, Furrie, Elizabeth, Jamieson, Scott, Dillon, John F

“…Thrombocytosis is often an incidental finding in primary care with a range of causes. Despite evidence of a strong association between thrombocytosis and…”
Get full text

Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT by Lee, Jeremy, Byrne, Christopher J., Brennan, Paul N., MacPherson, Iain, Dow, Eleanor, Dillon, John F.

“…Early diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), especially with advanced fibrosis, is crucial due to the increased risk of…”
Get full text

Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review protocol by Donaldson, Sarah R, Radley, Andrew, Dillon, John F

“…IntroductionHepatitis C virus (HCV) is a strongly stigmatised disease as it is framed within the context of injecting substance use. HCV provides the identity…”
Get full text

Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population by Innes, Hamish, McDonald, Scott, Hayes, Peter, Dillon, John F, Allen, Sam, Goldberg, David, Mills, Peter R, Barclay, Stephen T, Wilks, David, Valerio, Heather, Fox, Ray, Bhattacharyya, Diptendu, Kennedy, Nicholas, Morris, Judith, Fraser, Andrew, Stanley, Adrian, Bramley, Peter, Hutchinson, Sharon J

“…Graphical abstract…”
Get full text

Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts by Robinson, Emma, Byrne, Christopher J, Carberry, James, Radley, Andrew, Beer, Lewis J, Inglis, Sarah K, Tait, Jan, Macpherson, Iain, Goldberg, David, Hutchinson, Sharon J, Hickman, Matthew, Dillon, John F

“…Hepatitis C Virus (HCV) is a public health threat which contributes substantially to the global burden of liver disease. There is much debate about effective…”
Get full text

Intelligent Liver Function Testing (iLFT): An Intelligent Laboratory Approach to Identifying Chronic Liver Disease by Nobes, Jennifer, Leith, Damien, Handjiev, Sava, Dillon, John F, Dow, Ellie

“…The intelligent Liver Function Testing (iLFT) pathway is a novel, algorithm-based system which provides automated laboratory investigations and clinical…”
Get full text

Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world by Donaldson, Sarah R, Radley, Andrew, Dillon, John F

“…There has been a paradigm shift in the treatment of Hepatitis C (HCV) from the interferon-era to direct-acting antiviral (DAA) drugs. Cure of HCV for the key…”
Get full text

Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality by Pearson, Madeline, Nobes, Jennifer, Macpherson, Iain, Gold, Lucy, Miller, Michael, Dow, Ellie, Dillon, John F.

“…In community pathways for detection of liver disease the most common reason for referral is fibrosis assessment. We investigated the impact of adding the…”
Get full text

A multistakeholder approach to innovations in NAFLD care by Schattenberg, Jörn M., Allen, Alina M., Jarvis, Helen, Zelber-Sagi, Shira, Cusi, Ken, Dillon, John F., Caussy, Cyrielle, Francque, Sven M., Younossi, Zobair, Alkhouri, Naim, Lazarus, Jeffrey V.

“…Non-alcoholic fatty liver disease (NAFLD) is highly prevalent globally and requires multidisciplinary care. Here, we report key findings of a NAFLD care…”
Get full text

Long-term risk factors for developing Barrett’s oesophagus in patients with gastro-oesophageal reflux disease: a longitudinal cohort study by Byrne, Christopher J, Brennan, Paul, Carberry, James, Cotton, James, Dillon, John F

“…Background and aimsSeveral characteristics are known to affect the risk of Barrett’s oesophagus (BO) in the general population, with symptomatic…”
Get full text